Shree Amman Pharma India Private Limited, a active private limited company, was established on 25 May 2022 in Chennai, Tamil Nadu, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U24290TN2022PTC152555. Registered under ROC Roc Chennai. it is unlisted. It has an authorized capital of ₹7.20 Cr and a paid-up capital of ₹7.01 Cr.
It upholds a compliant status. Employing 101 professional, Its leadership includes Arvind Kumar Venkat (Director), Somu Baskaran (Managing Director), Balasubramaniam Jayakumar (Director). Past directors included Arvind Kumar Venkat, Gaurav Chaturvedi. It holds ₹30.65 Cr open charges and no settled loans. Its latest AGM occurred on 14 June 2025, with the balance sheet filed on 31 March 2025. It is based at New No. 9, Old No. 5, 7Th Street Gopalapuram, Chennai, Tamil Nadu, 600086.
U24290TN2022PTC152555
152555
25 May 2022
₹7.20 Cr
₹7.01 Cr
Roc Chennai
Unlisted
Active
Explore comprehensive insights into Shree Amman Pharma India Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arvind Kumar Venkat | Director | 20 Feb 2025 | Current |
| Somu Baskaran | Managing Director | 25 May 2022 | Current |
| Balasubramaniam Jayakumar | Director | 25 May 2022 | Current |
| Gaurav Chaturvedi | Director | 09 Jan 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 13 Jun 2025 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Shree Amman Pharma India Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2023, Shree Amman Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹306,500,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jul 2023 | Hdfc Bank Limited | ₹1.00 M | Open |
| 11 Jul 2023 | Hdfc Bank Limited | ₹30.55 Cr | Open |
Explore comprehensive loan charge details -
Shree Amman Pharma India has a workforce of 101 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Shree Amman Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Amman Pharma India's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Shree Amman Pharma India Private Limited last Annual general meeting of members was held on 14 Jun 2025 as per latest MCA records. was recorded as a recent event.
Progress on Shree Amman Pharma India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chennai. was documented.
Arvind Kumar Venkat was appointed as a Director was appointed as a Director on 20 Feb 2025 & has been associated with this company since 9 months 11 days . was recorded as a recent event.
Progress on Gaurav Chaturvedi was appointed as a Director was appointed as a Director on 09 Jan 2024 & has been associated with this company since 1 year 10 months . was documented.
A charge with Hdfc Bank Limited amounted to Rs. 0.10 Cr with Charge ID 100757073 was registered on 25 Jul 2023. was recorded as a recent event.
The activity A charge with Hdfc Bank Limited amounted to Rs. 30.55 Cr with Charge ID 100744341 was registered on 11 Jul 2023. was completed.
Pioneering access to this complex ophthalmic biosimilar medicine in the MENA Region Lupin has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer wit.
The CIN of Shree Amman Pharma India Private Limited is U24290TN2022PTC152555.
Shree Amman Pharma India Private Limited is headquartered at New No. 9, Old No. 5, 7Th Street Gopalapuram, Chennai, Tamil Nadu, 600086.
Shree Amman Pharma India Private Limited was incorporated on 25 May 2022.
The current directors of Shree Amman Pharma India Private Limited are
The primary industry of Shree Amman Pharma India Private Limited is Trade.
Shree Amman Pharma India Private Limited is unlisted.
The authorized capital of Shree Amman Pharma India Private Limited is ₹7.20 Cr, and the paid-up capital is ₹7.01 Cr.
The compliance status of Shree Amman Pharma India Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX